Sign up
Quantellect · Congress · Trade Detail
NYSE: GSKGlaxoSmithKline PLC ADR
RepublicanHouse

Pete Sessions sold GlaxoSmithKline PLC ADR (NYSE: GSK)

Pete Sessions (R-TX), a U.S. Representative, has disclosed 2 trades in GlaxoSmithKline PLC ADR (GSK) since 2017, 1 purchase and 1 sale, worth an estimated $16K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).

The trade highlighted here is a sale: Pete Sessions sold $1,001 - $15,000 of GlaxoSmithKline PLC ADR (NYSE: GSK) on August 31, 2017. Since that trade, GSK is up +98.35% against the S&P 500 up +238.26%, an outperformance of -139.91%.

Across these filings, Pete Sessions has been a balanced trader of GSK (a buy-to-sell ratio of 1.00). The most recent disclosed GSK transaction shown was dated October 25, 2017. Each row in the table below links to that trade and its post-trade performance versus the market.

Data updated

GSK trades
2
Disclosed Vol
$16K
Buys
1
50%
Sells
1
50%
Buy / Sell
1.00
ratio
First → Last
2017

Pete Sessions's GSK trades vs the price

GSK is up +98.35% since Pete Sessions sold on August 31, 2017, versus +238.26% for the S&P 500.

Performance since this trade

Price change since trade
+98.35%
S&P 500 change since trade
+238.26%
Outperformance vs S&P 500
-139.91%

All Pete Sessions GSK trades

TradedTypeSizeReturnEst. profit
October 25, 2017BUY$25.47+108.95%+$1K
August 31, 2017SELL$26.83+98.35%

Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.

Pete Sessions & GSK trading FAQ

Is it legal for Pete Sessions to trade GlaxoSmithKline PLC ADR (GSK) stock?

Yes. Members of Congress are allowed to trade individual stocks, including GlaxoSmithKline PLC ADR (GSK), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.

When did Pete Sessions sell GSK?

Pete Sessions disclosed a sale of $1,001 - $15,000 of GlaxoSmithKline PLC ADR (GSK) on August 31, 2017, according to public STOCK Act filings.

How has GSK performed since Pete Sessions's trade?

Since Pete Sessions sold GSK on August 31, 2017, the stock is up +98.35%, versus +238.26% for the S&P 500 over the same period, an outperformance of -139.91%.

How many times has Pete Sessions traded GSK?

Pete Sessions has disclosed 2 GSK trades since 2017 (1 purchase and 1 sale). Every disclosed trade is listed on this page.

How soon must members of Congress disclose a trade?

Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.

Where can I see all congressional GSK trades?

Quantellect tracks every disclosed congressional trade in GlaxoSmithKline PLC ADR (GSK) on the GlaxoSmithKline PLC ADR congressional trading page, which aggregates filings across all members of Congress.

Pete Sessions's GSK tradesAll congressional filings for GlaxoSmithKline PLC ADRPete Sessions's full profile

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.